United Kingdom's MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism

COPENHAGEN, Denmark, April 24, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the United Kingdom’s Medicines & Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for YORVIPATH® (palopegteriparatide; developed as TransCon™ PTH) in Great Britain as a parathyroid hormone (PTH) replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism, and has also granted YORVIPATH orphan drug status. YORVIPATH is a prod

Related Keywords

Copenhagen ,Køavn ,Denmark ,United States ,United Kingdom ,Japan ,Canada ,Canadian ,Great Britain ,Ascendis Pharma ,Endocrine Society Guidelines ,European Commission ,European Society Of Endocrinology Consensus Statement ,International Consensus Statement ,European Medicines Agency ,Exchange Commission ,Regulatory Agency ,Camilla Harder Harvig ,Executive Vice President ,Chief Commercial Officer ,Marketing Authorisation Application ,European Union ,Society Guidelines ,European Society ,Endocrinology Consensus ,Ascendi Annual Report ,Phra ,Parathyroid Hormone ,Hypoparathyroidism ,Forward Looking Statements ,